JP7494181B2 - 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 - Google Patents

置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 Download PDF

Info

Publication number
JP7494181B2
JP7494181B2 JP2021535539A JP2021535539A JP7494181B2 JP 7494181 B2 JP7494181 B2 JP 7494181B2 JP 2021535539 A JP2021535539 A JP 2021535539A JP 2021535539 A JP2021535539 A JP 2021535539A JP 7494181 B2 JP7494181 B2 JP 7494181B2
Authority
JP
Japan
Prior art keywords
compound
mmol
solvent
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514344A (ja
JP2022514344A5 (cg-RX-API-DMAC7.html
Inventor
アミランテ マッシモ
バフマンヤール ソゴール
ディー. コレア マシュー
グラント ヴァージニア
ハンセン ジョシュア
ジェイ. ホーン エヴァン
エス. ケルヒャー ティモシー
メイン クリストファー
エー. ナギー マーク
クリシュナ ナーラ ラマ
ナヤク スレンドラ
ノリス ステファン
パパ パトリック
プランテヴァン‐クレニツスキー ヴェロニク
ジェイ. サピエンザ ジョン
ダブリュー. ホワイトフィールド ブランドン
スー シュイチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022514344A publication Critical patent/JP2022514344A/ja
Publication of JP2022514344A5 publication Critical patent/JP2022514344A5/ja
Priority to JP2024083009A priority Critical patent/JP7724911B2/ja
Application granted granted Critical
Publication of JP7494181B2 publication Critical patent/JP7494181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2021535539A 2018-12-19 2019-12-18 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 Active JP7494181B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083009A JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US62/782,298 2018-12-19
US201962879900P 2019-07-29 2019-07-29
US62/879,900 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083009A Division JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Publications (3)

Publication Number Publication Date
JP2022514344A JP2022514344A (ja) 2022-02-10
JP2022514344A5 JP2022514344A5 (cg-RX-API-DMAC7.html) 2023-01-20
JP7494181B2 true JP7494181B2 (ja) 2024-06-03

Family

ID=71098067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535539A Active JP7494181B2 (ja) 2018-12-19 2019-12-18 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法
JP2024083009A Active JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083009A Active JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Country Status (29)

Country Link
US (4) US11149007B2 (cg-RX-API-DMAC7.html)
EP (2) EP3897636B1 (cg-RX-API-DMAC7.html)
JP (2) JP7494181B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250144505A (cg-RX-API-DMAC7.html)
CN (2) CN113453681B (cg-RX-API-DMAC7.html)
AU (1) AU2019403207B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011968A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124130A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001665A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007973A2 (cg-RX-API-DMAC7.html)
DK (1) DK3897636T3 (cg-RX-API-DMAC7.html)
ES (1) ES3009308T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897636T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250095T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070506T2 (cg-RX-API-DMAC7.html)
IL (1) IL284223B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897636T (cg-RX-API-DMAC7.html)
MX (1) MX2021007473A (cg-RX-API-DMAC7.html)
MY (1) MY205718A (cg-RX-API-DMAC7.html)
PE (1) PE20212247A1 (cg-RX-API-DMAC7.html)
PL (1) PL3897636T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897636T (cg-RX-API-DMAC7.html)
RS (1) RS66556B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106507RA (cg-RX-API-DMAC7.html)
SI (1) SI3897636T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500111T1 (cg-RX-API-DMAC7.html)
TW (1) TWI820276B (cg-RX-API-DMAC7.html)
WO (1) WO2020132014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104200B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109765A (ja) * 2018-12-19 2024-08-14 セルジーン コーポレイション 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
WO2022019597A1 (ko) * 2020-07-21 2022-01-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
AU2022240688B2 (en) * 2021-03-17 2024-07-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Furan fused ring-substituted glutarimide compound
EP4359404A4 (en) * 2021-06-25 2025-06-04 Celgene Corporation Cereblon-binding compounds, compositions thereof and methods of treatment therewith
KR20240026939A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20240026946A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US20260174749A1 (en) * 2022-11-09 2026-06-25 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6- dione compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025235600A1 (en) * 2024-05-07 2025-11-13 Bristol-Myers Squibb Company Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds
WO2025235577A1 (en) * 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501536A (ja) 1997-05-30 2002-01-15 セルジーン コーポレイション 置換2−(2,6−ジオキソピペリジン−3−イル)−フタルイミド類及び1−オキソイソインドリン類ならびにTNFαレベルの減少方法
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2013532657A (ja) 2010-07-22 2013-08-19 アンドレイ・アレクサンドロビッチ・イワシェンコ 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
JP2014510074A (ja) 2011-03-10 2014-04-24 スジョウ キンター ファーマシューティカルズ インコーポレイテッド アンドロゲン受容体アンタゴニストおよびその使用
JP2015526487A (ja) 2012-09-04 2015-09-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
WO2017123542A1 (en) 2016-01-11 2017-07-20 Janssen Pharmaceutica Nv Substituted thiohydantoin derivatives as androgen receptor antagonists
JP2017522379A (ja) 2014-07-08 2017-08-10 アール−ファーム オーバーシーズ インク.R−Pharm Overseas Inc. 置換2−チオキソ−イミダゾリジン−4−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法
US20180008587A1 (en) 2016-07-08 2018-01-11 Jaressen Pharmaceutica NV Thiohydantoin androgen receptor antagonists for the treatment of cancer
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
JP2022514347A (ja) 2018-12-19 2022-02-10 セルジーン コーポレイション 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
RU2747260C2 (ru) 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
HUE064356T2 (hu) 2017-11-28 2024-03-28 Aarti Pharmalabs Ltd Eljárás enzalutamid elõállítására új intermedier felhasználásával
CN111163638B (zh) 2017-12-05 2023-07-25 美国陶氏益农公司 杀有害生物组合物和方法
AU2019276514B2 (en) 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式(viii)的恩杂鲁胺的制备方法
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501536A (ja) 1997-05-30 2002-01-15 セルジーン コーポレイション 置換2−(2,6−ジオキソピペリジン−3−イル)−フタルイミド類及び1−オキソイソインドリン類ならびにTNFαレベルの減少方法
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2013532657A (ja) 2010-07-22 2013-08-19 アンドレイ・アレクサンドロビッチ・イワシェンコ 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
JP2014510074A (ja) 2011-03-10 2014-04-24 スジョウ キンター ファーマシューティカルズ インコーポレイテッド アンドロゲン受容体アンタゴニストおよびその使用
JP2015526487A (ja) 2012-09-04 2015-09-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
JP2017522379A (ja) 2014-07-08 2017-08-10 アール−ファーム オーバーシーズ インク.R−Pharm Overseas Inc. 置換2−チオキソ−イミダゾリジン−4−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017123542A1 (en) 2016-01-11 2017-07-20 Janssen Pharmaceutica Nv Substituted thiohydantoin derivatives as androgen receptor antagonists
US20180008587A1 (en) 2016-07-08 2018-01-11 Jaressen Pharmaceutica NV Thiohydantoin androgen receptor antagonists for the treatment of cancer
JP2022514347A (ja) 2018-12-19 2022-02-10 セルジーン コーポレイション 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109765A (ja) * 2018-12-19 2024-08-14 セルジーン コーポレイション 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法
JP7724911B2 (ja) 2018-12-19 2025-08-18 セルジーン コーポレイション 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Also Published As

Publication number Publication date
KR20250144505A (ko) 2025-10-10
US20240368083A1 (en) 2024-11-07
EP4494711A2 (en) 2025-01-22
IL284223B2 (en) 2025-08-01
MX2021007473A (es) 2021-08-05
US20200199073A1 (en) 2020-06-25
IL284223A (en) 2021-08-31
MY205718A (en) 2024-11-07
CL2021001665A1 (es) 2022-01-14
PE20212247A1 (es) 2021-11-24
WO2020132014A1 (en) 2020-06-25
TW202039435A (zh) 2020-11-01
JP2024109765A (ja) 2024-08-14
SG11202106507RA (en) 2021-07-29
US20230002321A1 (en) 2023-01-05
JP2022514344A (ja) 2022-02-10
CO2021007973A2 (es) 2021-09-09
CN119219606A (zh) 2024-12-31
PT3897636T (pt) 2025-01-27
SI3897636T1 (sl) 2025-04-30
RS66556B1 (sr) 2025-03-31
SMT202500111T1 (it) 2025-05-12
US20260193185A1 (en) 2026-07-09
HRP20250095T1 (hr) 2025-04-11
CA3124130A1 (en) 2020-06-25
EP3897636A4 (en) 2022-09-07
EP4494711A3 (en) 2025-05-21
AU2019403207A1 (en) 2021-07-15
BR112021011968A2 (pt) 2021-09-08
LT3897636T (lt) 2025-03-25
CN113453681B (zh) 2024-10-11
AU2019403207B2 (en) 2025-06-05
US11873283B2 (en) 2024-01-16
CN113453681A (zh) 2021-09-28
DK3897636T3 (da) 2025-01-13
ES3009308T3 (en) 2025-03-26
JP7724911B2 (ja) 2025-08-18
NZ777281A (en) 2025-07-25
PL3897636T3 (pl) 2025-04-28
FI3897636T3 (fi) 2025-02-03
KR20210118816A (ko) 2021-10-01
HUE070506T2 (hu) 2025-06-28
US11149007B2 (en) 2021-10-19
KR102866144B1 (ko) 2025-09-30
EP3897636A1 (en) 2021-10-27
TWI820276B (zh) 2023-11-01
ZA202104200B (en) 2024-11-27
IL284223B1 (en) 2025-04-01
EP3897636B1 (en) 2024-12-11
US12404241B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
US12404241B2 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7492962B2 (ja) 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法
JP7781083B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
HK40061385A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
HK40061385B (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
EA044376B1 (ru) Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526192A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240522

R150 Certificate of patent or registration of utility model

Ref document number: 7494181

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150